Nektar Therapeutics Closes $115 Million Public Offering with Full Exercise of Underwriters' Option

Reuters
03 Jul
Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Closes $115 Million Public Offering with Full Exercise of Underwriters' Option

Nektar Therapeutics, a clinical-stage biotechnology company specializing in immunotherapy, has successfully closed a public offering, raising $115 million. The company sold 4,893,618 shares of its common stock, which includes an additional 638,298 shares sold following the full exercise of the underwriters' option to purchase extra shares. The shares were sold at a price of $23.50 each. The proceeds from this offering will be used for general corporate purposes, including research, clinical development, and manufacturing costs to advance Nektar's drug candidates. Jefferies and Piper Sandler served as joint bookrunning managers for the offering, with BTIG, LLC and H.C. Wainwright & Co. also participating in management roles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF23169) on July 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10